不同促性腺激素释放激素激动剂治疗子宫内膜异位症的应用情况和疗效分析

Analysis of the Treatment and Efficacy of Different Gonadotropin-releasing Hormone Agonist for the Treatment of Endometriosis

目的探讨促性腺激素释放激素激动剂(gonadotropin-releasing hormone agonist,GnRHa)在子宫内膜异位症的应用情况,并比较不同GnRHa的疗效。方法利用医院计算机处方管理系统提取2018年1月1日-2019年1月1日门诊药房调配含有GnRHa的处方信息,分析和讨论亮丙瑞林、戈舍瑞林、曲普瑞林用于治疗子宫内膜异位症的比例,并研究不同GnRHa对子宫异常出血、内膜厚度及CA125的影响。结果亮丙瑞林、戈舍瑞林、曲普瑞林在子宫内膜异位症的使用比例分别为29.45%,46.52%,24.03%;不同GnRHa用药前后子宫内膜厚度、子宫体积和CA125无显著性差异;子宫不规则出血病例数曲普瑞林最多,亮丙瑞林最少。结论不同GnRHa疗效无明显差异,使用比例不同可能与药物的安全性、经济性,医师的地域性、使用习惯有关。

OBJECTIVE To investigate the application of gonadotropin-releasing hormone agonist(GnRHa) in endometriosis and analyze the efficacy of different GnRHa. METHODS Using the hospital computer prescription management system to transfer the prescription information of GnRHa in the outpatient pharmacy from January 1, 2018 to January 1, 2019. The proportion of patients with endometriosis treated with leuprolide, goserelin, triptorelin was analyzed, and the effects of different GnRHa on abnormal uterine bleeding, intimal thickness and CA125 were studied. RESULTS The use ratio of leuprolide goserelin, tri-ptorelin in endometriosis was 29.45%, 46.52%, and 24.03%, respectively. There was no significant difference in thickness of endometrium, uterine volume and CA125 before and after treatment with different GnRHa;the number of irregular uterine bleeding was the highest in triptorelin and the lowest in leuprolide. CONCLUSION There is no significant difference in the efficacy of different GnRHa. The reasons for the high or low proportion of GnRHa may be related to the safety, economy of drug, regionality and habits of doctor.